169 related articles for article (PubMed ID: 21714970)
1. Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation.
Rogueda PG; Price R; Smith T; Young PM; Traini D
J Colloid Interface Sci; 2011 Sep; 361(2):649-55. PubMed ID: 21714970
[TBL] [Abstract][Full Text] [Related]
2. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
[TBL] [Abstract][Full Text] [Related]
3. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
Hampel FC; Martin P; Mezzanotte WS
J Asthma; 2008 May; 45(4):265-72. PubMed ID: 18446589
[TBL] [Abstract][Full Text] [Related]
4. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers.
Traini D; Young PM; Rogueda P; Price R
Pharm Res; 2007 Jan; 24(1):125-35. PubMed ID: 17103336
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
[TBL] [Abstract][Full Text] [Related]
6. Can low-dose combination products for inhalation be formulated in single crystalline particles?
Kumon M; Kwok PC; Adi H; Heng D; Chan HK
Eur J Pharm Sci; 2010 Apr; 40(1):16-24. PubMed ID: 20172026
[TBL] [Abstract][Full Text] [Related]
7. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Tarsin WY; Pearson SB; Assi KH; Chrystyn H
Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler.
Chambers F; Ludzik A
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):113-20. PubMed ID: 19422311
[TBL] [Abstract][Full Text] [Related]
9. Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.
Murnane D; Martin GP; Marriott C
Pharm Res; 2008 Oct; 25(10):2283-91. PubMed ID: 18509598
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
[TBL] [Abstract][Full Text] [Related]
11. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
[TBL] [Abstract][Full Text] [Related]
12. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers.
Adi H; Young PM; Traini D
J Pharm Pharmacol; 2012 Sep; 64(9):1245-53. PubMed ID: 22881437
[TBL] [Abstract][Full Text] [Related]
13. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
15. Long-acting reliever/preventer inhalers.
Nurs Times; 2005 Oct 25-31; 101(43):31. PubMed ID: 16276841
[No Abstract] [Full Text] [Related]
16. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
Blais L; Beauchesne MF; Forget A
Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
[TBL] [Abstract][Full Text] [Related]
17. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler.
Nagel MW; Wiersema KJ; Bates SL; Mitchell JP
J Aerosol Med; 2002; 15(4):427-33. PubMed ID: 12581509
[TBL] [Abstract][Full Text] [Related]
18. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
19. Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics.
Berlinski A; Pennington D
Respir Care; 2017 Sep; 62(9):1123-1130. PubMed ID: 28611228
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy.
Ashayer R; Luckham PF; Manimaaran S; Rogueda P
Eur J Pharm Sci; 2004 Mar; 21(4):533-43. PubMed ID: 14998585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
